miR-125b对肝癌干细胞自我更新能力的调控作用  

miR-125b regulates self-renewal in liver cancer stem cells

作　　者：彭维[1] 赵湘湘[2] 苏立[1] 钱程[1] 

机构地区：[1]第三军医大学西南医院全军临床病理学研究所,重庆400038 [2]浙江理工大学生命科学学院,杭州310018

出　　处：《第三军医大学学报》2015年第11期1070-1074,共5页Journal of Third Military Medical University

基　　金：国家自然科学基金青年科学基金(81301959)~~

摘　　要：目的观察miR-125b对肝癌干细胞(liver cancer stem cells,LCSCs)成球、克隆形成、增殖、凋亡、迁移的作用,探讨miR-125b对肝癌干细胞自我更新能力的调控作用。方法获取肝癌干细胞;包装表达miR-125b的慢病毒并感染肝癌干细胞;光镜计数法检测miR-125b对肝癌干细胞成球率及克隆形成率的影响;CCK-8法检测miR-125b对肝癌干细胞增殖能力的影响;DAPI染色观察miR-125b对肝癌干细胞凋亡的影响;Transwell实验检测miR-125b对肝癌干细胞迁移能力的影响。结果与对照组比较,miR-125b显著降低LCSCs的成球率(对照组27.7%,实验组0.0%,P<0.01)以及抑制其克隆形成能力(对照组29%,实验组6%,P<0.01);同时miR-125b可促进LCSCs的凋亡,抑制LCSCs的迁移能力(P<0.01)。结论 miR-125b对LCSCs的成球能力、克隆形成能力具有明显的抑制作用,表明miR-125b对LCSCs的自我更新能力具有负向调控作用。miR-125b也能抑制LCSCs的迁移,对LCSCs的凋亡具有促进作用。Objective To determine the effects of miR-125b on the sphere formation, clone formation, proliferation, apoptosis and migration of liver cancer stem cells （ LCSCs ） , and investigate the regulative role of miR-125b on the self-renewal capacity of LCSCs. Methods The lentivirus expressing miR- 125b was used to infect obtained LCSCs. Light microscope counting was employed to measure the sphere formation and clone formation in the infected LCSCs. CCK-8 assay was used to detect the effect of miR-125b on the proliferation of LCSCs. DAPI staining and transwell chamber test was used to observe the effect of miR-125b on the cell apoptosis and migration. Results Compared with the control cells, miR-125b significant decreased sphere formation （0.0% vs 27.7%, P 〈0.01 ）, inhibited the colony formation （6% vs 29%, P 〈0. 01 ）, promoted the cell apoptosis, and inhibited the migration ability in LCSCs after lentivirus infection （P 〈 0.01 ）. Conclusion miR-125b exerts significant inhibitory effect on sphere and clone formation of LCSCs, indicating its negative role in the regulation of self-renewal capacity of the stem ceils. It also can inhibit the migration and promote the apoptosis of LCSCs.

关 键 词：miR-125b 肝癌干细胞 自我更新 

分 类 号：R73-354[医药卫生—肿瘤] R735.7[医药卫生—临床医学]